Hyperglycaemia is an abnormally elevated blood glucose level (fasting >100 mg/dL or 5.6 mmol/L) resulting from impaired cellular glucose uptake, excessive hepatic glucose production, or both. It represents metabolic inflexibility where glucose cannot transition from bloodstream to intracellular energy production, triggering inflammatory, oxidative, and glycation cascades that damage multiple organ systems. This is not simply "too much sugar" but a failure of the fundamental cellular fuel delivery system.
Imagine a city (your body) where delivery trucks (glucose molecules) are circling the streets but can't unload their cargo at warehouses (muscle and fat cells). The warehouses have locked gates (insulin resistance at GLUT4 receptors), so trucks pile up on the roads, creating traffic jams (hyperglycaemia). Meanwhile, the central factory (liver) keeps producing more trucks (gluconeogenesis) because it hasn't received the "stop production" signal. As trucks accumulate, their cargo starts leaking sticky syrup onto everything—road signs (proteins), streetlights (enzymes), even the pavement itself (extracellular matrix). This sticky coating (glycation → AGEs) makes infrastructure brittle and dysfunctional. The excess trucks also emit exhaust fumes (ROS from mitochondrial overflow), corroding metal structures (oxidative damage to lipids and DNA). Traffic cops (immune cells) show up, but the chaos confuses them—they start directing traffic erratically (inflammatory activation via NF-κB), sometimes blocking legitimate deliveries. In hunter phenotypes, the warehouse gates are built with especially rigid hinges (curved clathrin structure), making them even harder to open, so traffic jams happen faster and with fewer trucks on the road.
Hyperglycaemia develops through multiple converging pathways, all representing failures in the glucose disposal and production balance:
Cellular Uptake Failure:
- Insulin binds to insulin receptors on muscle and adipose tissue
- Normally triggers PI3K → Akt pathway → GLUT4 translocation to membrane
- In insulin resistance: Akt signalling impaired → GLUT4 remains sequestered in intracellular vesicles by clathrin-coated pits
- In hunter phenotype: clathrin protein structure is more curved/rigid → spontaneous GLUT4 translocation severely limited even with insulin present
- Result: glucose cannot enter cells despite adequate insulin
Hepatic Overproduction:
- Insulin normally suppresses hepatic gluconeogenesis via FOXO1 phosphorylation and nuclear exclusion
- In insulin resistance: FOXO1 remains active → increased expression of PEPCK and G6Pase (gluconeogenic enzymes)
- Elevated cortisol (chronic stress) → synergistic activation of gluconeogenesis
- Free fatty acids from visceral adiposity → drive hepatic glucose output via acetyl-CoA → pyruvate carboxylase activation
- Result: liver continues producing glucose regardless of blood levels
Downstream Damage Cascades:
graph TD
A[Elevated Blood Glucose] --> B[Mitochondrial Overload]
A --> C[Non-Enzymatic Glycation]
A --> D[Osmotic Effects]
B --> B1[Electron Transport Chain Saturation]
B1 --> B2[Increased ROS Production]
B2 --> B3[Oxidative Damage to Lipids/DNA/Proteins]
B2 --> B4["NF-κB Activation"]
C --> C1["Glucose + Protein Amino Groups"]
C1 --> C2[Schiff Base Formation]
C2 --> C3[Amadori Products]
C3 --> C4[Advanced Glycation End-Products AGEs]
C4 --> C5[RAGE Receptor Activation]
C5 --> C6["NF-κB → IL-6, TNF-α"]
C4 --> C7[Collagen Cross-linking]
C7 --> C8[Vessel Stiffness]
D --> D1[Hyperosmolar State]
D1 --> D2[Minimal Vasopressin Response]
D1 --> D3[Osmotic Diuresis]
B4 --> E[Inflammatory Cascade]
C6 --> E
E --> F[Endothelial Dysfunction]
E --> G[Immune Dysregulation]
F --> F1[Reduced NO Production]
F1 --> F2[Impaired Vasodilation]
F --> F3[Increased VCAM-1/ICAM-1]
F3 --> F4[Monocyte Adhesion]
G --> G1[Impaired Neutrophil Chemotaxis]
G --> G2[Reduced Phagocytosis]
G --> G3[Increased Infection Risk]
Specific Molecular Events:
-
Glycation Pathway: Glucose (aldehyde group) + lysine/arginine residues → reversible Schiff base → Amadori rearrangement → irreversible AGEs. AGEs bind RAGE (receptor for AGEs) → activates NF-κB → transcription of IL-6, TNF-α, IL-1β genes.
-
Oxidative Stress: Excess glucose → mitochondrial TCA cycle overload → increased NADH/NAD+ ratio → complex I and III electron leak → superoxide (O2•−) production → hydrogen peroxide (H2O2) → hydroxyl radical (•OH) via Fenton reaction. Overwhelms SOD, catalase, glutathione systems.
-
Inflammatory Activation: ROS + AGE-RAGE signaling → IκB phosphorylation by IKK → IκB degradation → NF-κB nuclear translocation → inflammatory gene transcription. Positive feedback: inflammatory cytokines worsen insulin resistance.
-
Hunter Phenotype Mechanism: Polymorphism in clathrin heavy chain gene (CHC22) produces more curved clathrin structure → GLUT4 vesicles more tightly held in "coated pit" conformation → insulin-stimulated GLUT4 translocation requires higher insulin concentration → hyperglycaemia develops at lower glucose loads (threshold ~100 mg/dL vs ~126 mg/dL in farmers).
-
Vascular Damage: AGE cross-linking of collagen → arterial stiffness. Endothelial NO synthase (eNOS) glycation → reduced NO production → vasoconstriction + platelet aggregation. Basement membrane thickening in retina, kidney, peripheral nerves → microvascular complications.
-
Immune Impairment: Glucose competes with vitamin C for GLUT1 transporters on neutrophils → reduced intracellular ascorbate → impaired oxidative burst. High glucose → neutrophil adhesion molecule downregulation → poor migration to infection sites. Chronic hyperglycaemia associated with 2-3× infection risk.
Diagnostic Thresholds and Hunter-Farmer Divergence:
Hyperglycaemia is the cardinal metabolic marker distinguishing hunter from farmer phenotypes. Hunters manifest hyperglycaemia at fasting glucose ≥100 mg/dL (5.6 mmol/L) due to rigid clathrin structure limiting GLUT4 availability. Farmers typically require ≥126 mg/dL (7.0 mmol/L) for diabetes diagnosis. This 26 mg/dL gap represents fundamental evolutionary divergence in glucose handling architecture. HbA1c >5.7% indicates 2-3 month average glucose elevation and predicts progression to overt diabetes.
Metamodel Integration:
- Metamodel 1 (Evolutionary Mismatch): Hyperglycaemia represents mismatch between Palaeolithic genome optimized for intermittent fasting and modern chronic carbohydrate exposure. Hunter phenotype particularly vulnerable—selected for metabolic efficiency in scarcity, maladaptive in abundance.
- Metamodel 2 (Selfish Systems): The selfish brain prioritizes its own glucose supply via stress-axis-driven gluconeogenesis, creating systemic hyperglycaemia that damages peripheral tissues. Reflects evolutionary priority of CNS survival over long-term metabolic health.
- Metamodel 3 (Inflammatory Resolution Failure): Chronic hyperglycaemia impairs specialized pro-resolving mediator (SPM) synthesis—high glucose inhibits 15-LOX and 5-LOX enzymes required for resolvin/protectin/maresin production. Inflammation becomes stuck in initiation phase.
Clinical Presentation and System Failures:
Hyperglycaemia is never an isolated finding—it signals multi-system metabolic dysfunction. Patients present with fatigue (cellular energy starvation despite high circulating glucose), recurrent infections (impaired neutrophil function), delayed wound healing (collagen synthesis disruption), peripheral neuropathy (small fiber damage from glycation), visual changes (retinal basement membrane thickening), and cognitive dysfunction (hippocampal neuroinflammation from AGEs).
Intervention Targets:
Treatment must address root causes, not just glucose lowering:
- Clathrin Structure Modification: Resistance training increases muscle GLUT1 expression (insulin-independent) and may alter clathrin dynamics through mechanotransduction
- Hepatic Gluconeogenesis Suppression: Time-restricted feeding (16:8), cold exposure (via AMPK activation), berberine (AMPK activator mimicking metformin)
- AGE Formation Prevention: Glycine supplementation (competes with glucose for protein binding sites), carnosine (AGE scavenger), low-AGE cooking methods (avoid high-heat, dry cooking)
- Oxidative Stress Reduction: Mitochondrial support via CoQ10, alpha-lipoic acid, PQQ; upregulate antioxidant defenses via Nrf2 activation (sulforaphane, resveratrol)
- Inflammatory Resolution: Omega-3 fatty acids (EPA/DHA) to restore SPM synthesis capacity; curcumin to inhibit NF-κB
Monitoring Strategy:
Fasting glucose alone is insufficient—use continuous glucose monitoring to detect postprandial spikes and glycemic variability (strong predictor of complications). HbA1c captures 2-3 month average but misses daily fluctuations. Fructosamine (2-3 week marker) useful for shorter-term tracking. Advanced markers: 1,5-anhydroglucitol (sensitive to postprandial hyperglycaemia), methylglyoxal (AGE precursor), serum AGEs.
- Fasting glucose >100 mg/dL defines prediabetes; >126 mg/dL defines diabetes (ADA criteria)
- Hunter phenotype threshold: Blood glucose ≥100 mg/dL triggers metabolic dysfunction due to clathrin structure rigidity
- HbA1c >5.7% indicates chronic hyperglycaemia with 3-6× increased diabetes risk over 5 years
- Glycation rate: Each 1% HbA1c increase = ~35 mg/dL average glucose rise
- AGE formation kinetics: Irreversible after 6-8 weeks of elevated glucose; collagen turnover extremely slow (years), so vascular AGEs persist
- Mitochondrial ROS production: Increases 3-fold when glucose >180 mg/dL; threshold for oxidative damage
- Infection risk: 2-3× higher in chronic hyperglycaemia; neutrophil chemotaxis reduced by 50% at glucose >200 mg/dL
- Osmotic threshold: Glucose >270 mg/dL (15 mmol/L) triggers minimal vasopressin response and osmotic diuresis
- Neuroinflammation: Hippocampal microglial activation detectable at HbA1c >6.0%; correlates with cognitive decline
- Postprandial spikes: Glucose variability (standard deviation >30 mg/dL) predicts cardiovascular events independent of HbA1c
- Clathrin polymorphism (CHC22): Present in ~40% Northern European ancestry; confers hunter phenotype susceptibility
- GLUT4 translocation: Requires 50-100× more insulin signal in hunter phenotype vs farmer for equivalent glucose uptake
- insulin resistance — primary driver of hyperglycaemia; post-receptor defect prevents GLUT4 translocation despite adequate insulin
- GLUT4 — insulin-dependent glucose transporter; sequestration in clathrin-coated vesicles causes cellular glucose starvation amid hyperglycaemia
- hunter phenotype — curved clathrin structure (CHC22 polymorphism) limits spontaneous GLUT4 membrane insertion; hyperglycaemia threshold ~100 mg/dL
- clatrin — structural protein determining GLUT4 vesicle mobility; rigid curved form in hunters prevents insulin-independent glucose uptake
- metabolic syndrome — hyperglycaemia is 1 of 5 diagnostic criteria; coexists with visceral adiposity, dyslipidaemia, hypertension, inflammation
- type 2 diabetes — chronic hyperglycaemia defining feature (fasting glucose ≥126 mg/dL); endpoint of progressive insulin resistance
- AGEs — advanced glycation end-products formed by non-enzymatic glucose-protein binding; activate RAGE receptors driving inflammation
- inflammation — hyperglycaemia activates NF-κB via ROS and AGE-RAGE signaling; drives IL-6, TNF-α, IL-1β transcription
- oxidative stress — mitochondrial electron transport chain overload from excess glucose generates superoxide, hydrogen peroxide, hydroxyl radicals
- HbA1c — glycated haemoglobin; integrates 2-3 month average glucose; each 1% increase = ~35 mg/dL glucose rise
- gluconeogenesis — hepatic glucose production via PEPCK and G6Pase; dysregulated in hyperglycaemia due to FOXO1 activation
- endothelial dysfunction — AGE-induced collagen cross-linking stiffens vessels; eNOS glycation reduces NO production impairing vasodilation
- atherosclerosis — hyperglycaemia accelerates plaque formation via oxidized LDL, endothelial activation (VCAM-1), monocyte adhesion
- neuropathy — small fibre damage from AGE deposition in nerve basement membranes and Schwann cell dysfunction
- hyperinsulinaemia — compensatory pancreatic beta-cell response attempting to overcome insulin resistance; precedes hyperglycaemia
- visceral adiposity — ectopic fat releases free fatty acids driving hepatic insulin resistance and gluconeogenesis
- cortisol — chronic elevation activates hepatic gluconeogenesis via PEPCK/G6Pase transcription; synergizes with glucagon
- glycolysis — impaired in hyperglycaemia despite high substrate due to GLUT4 dysfunction; creates cellular energy deficit
- vasopressin — minimal secretion response at extreme hyperglycaemia (>270 mg/dL); osmotic threshold dysfunction
- immune function — neutrophil chemotaxis reduced 50% at glucose >200 mg/dL; vitamin C competition at GLUT1 impairs oxidative burst
- NF-κB — master inflammatory transcription factor activated by hyperglycaemia-induced ROS and AGE-RAGE signaling
- FOXO1 — transcription factor driving gluconeogenic gene expression; remains nuclear-active in insulin resistance
- mitochondrial dysfunction — electron transport chain saturation from glucose overload; complex I/III ROS generation
- small fibre neuropathy — C-fibre and A-delta fibre damage from chronic hyperglycaemia; basement membrane AGE deposition
- neuroinflammation — hippocampal microglial activation from AGE-RAGE signaling; impairs adult neurogenesis and memory consolidation
- specialized pro-resolving mediators (SPMs) — synthesis impaired by hyperglycaemia; high glucose inhibits 15-LOX and 5-LOX enzymes
- collagen — AGE cross-linking increases stiffness and fragility; impairs wound healing and vascular compliance
- neutrophils — chemotaxis and phagocytosis impaired in hyperglycaemia; increased infection susceptibility
- RAGE — receptor for AGEs; activation triggers NF-κB inflammatory cascade and perpetuates oxidative stress
- time-restricted eating — intervention suppressing nocturnal gluconeogenesis via AMPK activation and circadian CLOCK gene regulation
- Module 1 — Evolutionary medicine foundations; hunter vs farmer phenotype divergence in glucose metabolism
- Module 2 — Neuroendocrine regulation of glucose homeostasis; hypothalamic inflammation and metabolic dysregulation
- Module 3 — Immunometabolism; how hyperglycaemia impairs immune cell function and resolution capacity
- Module 4 — Gut-liver axis; intestinal permeability, endotoxemia, and hepatic insulin resistance driving hyperglycaemia
- Module 8 — Clinical diagnostics; interpreting glucose markers, HbA1c, and designing personalized interventions for metabolic inflexibility